Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Dec 23

PMID 38139212

Authors

Muftah Mahmud

Swati Vasireddy

Krisstina Gowin

Akshay Amaraneni

Affiliations

Soon will be listed here.

Abstract

Myelofibrosis (MF), Myeloproliferative neoplasms (MPNs), and MDS/MPN overlap syndromes have a broad range of clinical presentations and molecular abnormalities, making their diagnosis and classification complex. This paper reviews molecular aberration, epigenetic modifications, chromosomal anomalies, and their interactions with cellular and other immune mechanisms in the manifestations of these disease spectra, clinical features, classification, and treatment modalities. The advent of new-generation sequencing has broadened the understanding of the genetic factors involved. However, while great strides have been made in the pharmacological treatment of these diseases, treatment of advanced disease remains hematopoietic stem cell transplant.

Citing Articles

Biological Markers of Myeloproliferative Neoplasms in Children, Adolescents and Young Adults.

Ozygala A, Rokosz-Mierzwa J, Widz P, Skowera P, Wilinski M, Styka B Cancers (Basel). 2024; 16(23).

PMID: 39682300 PMC: 11640741. DOI: 10.3390/cancers16234114.

References

Ajufo H, Waksal J, Mascarenhas J, Rampal R . Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges. Ther Adv Hematol. 2023; 14:20406207231177282. PMC: 10410182. DOI: 10.1177/20406207231177282. View

Ramanathan G, Fleischman A . The Microenvironment in Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2021; 35(2):205-216. PMC: 8832361. DOI: 10.1016/j.hoc.2020.11.003. View

Milosevic J, Puda A, Malcovati L, Berg T, Hofbauer M, Stukalov A . Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol. 2012; 87(11):1010-6. DOI: 10.1002/ajh.23309. View

Schepers K, Pietras E, Reynaud D, Flach J, Binnewies M, Garg T . Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013; 13(3):285-99. PMC: 3769504. DOI: 10.1016/j.stem.2013.06.009. View

Lasho T, Mudireddy M, Finke C, Hanson C, Ketterling R, Szuber N . Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Adv. 2018; 2(4):370-380. PMC: 5858483. DOI: 10.1182/bloodadvances.2018015875. View

Farina M, Bernardi S, Polverelli N, DAdda M, Malagola M, Bosio K . Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis. Cells. 2021; 10(10). PMC: 8534986. DOI: 10.3390/cells10102764. View

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

Easwar A, Siddon A . Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing. Life (Basel). 2021; 11(11). PMC: 8625510. DOI: 10.3390/life11111158. View

Nam A, Kim K, Chaligne R, Izzo F, Ang C, Taylor J . Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature. 2019; 571(7765):355-360. PMC: 6782071. DOI: 10.1038/s41586-019-1367-0. View

10.

Mangaonkar A, Swoboda D, Coltro G, Lasho T, Novotny P, Pophali P . Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia. 2019; 34(2):656-661. DOI: 10.1038/s41375-019-0574-x. View

11.

Verstovsek S, Yu J, Kish J, Paranagama D, Kaufman J, Myerscough C . Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States. Ann Hematol. 2020; 99(11):2555-2564. PMC: 7536164. DOI: 10.1007/s00277-020-04055-w. View

12.

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

13.

Tefferi A, Saeed L, Hanson C, Ketterling R, Pardanani A, Gangat N . Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. Leukemia. 2017; 31(12):2851-2852. PMC: 5729329. DOI: 10.1038/leu.2017.268. View

14.

Skov V, Riley C, Thomassen M, Larsen T, Jensen M, Bjerrum O . Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leuk Lymphoma. 2013; 54(10):2269-73. DOI: 10.3109/10428194.2013.764417. View

15.

Lasho T, Jimma T, Finke C, Patnaik M, Hanson C, Ketterling R . SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012; 120(20):4168-71. DOI: 10.1182/blood-2012-05-429696. View

16.

Saleiro D, Wen J, Kosciuczuk E, Eckerdt F, Beauchamp E, Oku C . Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms. Nat Commun. 2022; 13(1):1750. PMC: 8975834. DOI: 10.1038/s41467-022-29381-7. View

17.

Roman E, Smith A, Appleton S, Crouch S, Kelly R, Kinsey S . Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15. Cancer Epidemiol. 2016; 42:186-98. PMC: 4911595. DOI: 10.1016/j.canep.2016.03.011. View

18.

Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H . Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019; 129(4):1596-1611. PMC: 6436863. DOI: 10.1172/JCI98785. View

19.

Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A . Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011; 29(10):1356-63. DOI: 10.1200/JCO.2010.32.9490. View

20.

Rumi E, Cazzola M . Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2016; 129(6):680-692. PMC: 5335805. DOI: 10.1182/blood-2016-10-695957. View